Health TrialsbyHealthPanel

Clinical trials

2

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CITY-FXI in Healthy Adults, Adults With FV Leiden or Prothrombin G20210A Mutation, and Adults With a History of Provoked Venous Thromboembolism

This is a first-in-human (FIH), single-center, randomized, double-blind, placebo-controlled, single ascending and multiple dose study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CITY-FXI in healthy adults, adults with Factor V Leiden (FVL) or prothrombin G20210A mutation, and adults with a history of provoked venous thromboembolism (VTE).

Participants needed: 182
Trial details
Phase: Phase 1Age: 18-65Biological sex: AllType: InterventionalSponsor: City TherapeuticsUpdated: Sep 25, 2026Locations: 1
Eligibility criteria

Males and women of non-childbearing potential (WONCBP) aged 18 to 45 years (incl... [+6]

Any clinically significant systemic disease or disorder, including but not limit... [+4]

Read more
Status: Recruiting

A Phase 1, First-in-Human Study of CITY-RBP4 in Healthy Volunteers and STGD1 Participants

This is a first-in-human (FIH), multicenter, randomized, double-masked, placebo-controlled adaptive clinical study evaluating the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) of CITY-RBP4, following single-ascending doses and multiple doses, via subcutaneous (SC) administration.

Participants needed: 48
Trial details
Phase: Phase 1Age: 12-45Biological sex: AllType: InterventionalSponsor: City TherapeuticsUpdated: Sep 23, 2026Locations: 1
Eligibility criteria

Willing and able to provide written informed consent form [+7]

Clinically significant ocular disease or prior ocular surgery that could interfe... [+18]

Read more